CERS
Price
$1.48
Change
-$0.03 (-1.99%)
Updated
Jun 9, 04:59 PM (EDT)
Capitalization
342.62M
52 days until earnings call
STXS
Price
$2.33
Change
+$0.08 (+3.56%)
Updated
Jun 9, 04:59 PM (EDT)
Capitalization
214.36M
59 days until earnings call
Interact to see
Advertisement

CERS vs STXS

Header iconCERS vs STXS Comparison
Open Charts CERS vs STXSBanner chart's image
Cerus
Price$1.48
Change-$0.03 (-1.99%)
Volume$21.36K
Capitalization342.62M
Stereotaxis
Price$2.33
Change+$0.08 (+3.56%)
Volume$15.01K
Capitalization214.36M
CERS vs STXS Comparison Chart
Loading...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CERS vs. STXS commentary
Jun 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a StrongBuy and STXS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 10, 2025
Stock price -- (CERS: $1.26 vs. STXS: $2.10)
Brand notoriety: CERS and STXS are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CERS: 83% vs. STXS: 46%
Market capitalization -- CERS: $342.62M vs. STXS: $214.36M
CERS [@Medical Specialties] is valued at $342.62M. STXS’s [@Medical Specialties] market capitalization is $214.36M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.58B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 0 FA rating(s) are green whileSTXS’s FA Score has 0 green FA rating(s).

  • CERS’s FA Score: 0 green, 5 red.
  • STXS’s FA Score: 0 green, 5 red.
According to our system of comparison, CERS is a better buy in the long-term than STXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 3 TA indicator(s) are bullish while STXS’s TA Score has 3 bullish TA indicator(s).

  • CERS’s TA Score: 3 bullish, 4 bearish.
  • STXS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CERS is a better buy in the short-term than STXS.

Price Growth

CERS (@Medical Specialties) experienced а +1.20% price change this week, while STXS (@Medical Specialties) price change was +2.94% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +3.37%. For the same industry, the average monthly price growth was +5.59%, and the average quarterly price growth was +1.68%.

Reported Earning Dates

CERS is expected to report earnings on Jul 31, 2025.

STXS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Medical Specialties (+3.37% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CERS($343M) has a higher market cap than STXS($214M). STXS YTD gains are higher at: -7.895 vs. CERS (-17.857). STXS has higher annual earnings (EBITDA): -21.24M vs. CERS (-26.34M). CERS has more cash in the bank: 65.9M vs. STXS (19.8M). STXS has less debt than CERS: STXS (5.49M) vs CERS (96M). CERS has higher revenues than STXS: CERS (156M) vs STXS (26.8M).
CERSSTXSCERS / STXS
Capitalization343M214M160%
EBITDA-26.34M-21.24M124%
Gain YTD-17.857-7.895226%
P/E RatioN/AN/A-
Revenue156M26.8M582%
Total Cash65.9M19.8M333%
Total Debt96M5.49M1,749%
FUNDAMENTALS RATINGS
CERS vs STXS: Fundamental Ratings
CERS
STXS
OUTLOOK RATING
1..100
1420
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
8452
P/E GROWTH RATING
1..100
10061
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CERS's Valuation (43) in the Medical Specialties industry is somewhat better than the same rating for STXS (92). This means that CERS’s stock grew somewhat faster than STXS’s over the last 12 months.

CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as STXS (100). This means that CERS’s stock grew similarly to STXS’s over the last 12 months.

CERS's SMR Rating (97) in the Medical Specialties industry is in the same range as STXS (100). This means that CERS’s stock grew similarly to STXS’s over the last 12 months.

STXS's Price Growth Rating (52) in the Medical Specialties industry is in the same range as CERS (84). This means that STXS’s stock grew similarly to CERS’s over the last 12 months.

STXS's P/E Growth Rating (61) in the Medical Specialties industry is somewhat better than the same rating for CERS (100). This means that STXS’s stock grew somewhat faster than CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSSTXS
RSI
ODDS (%)
N/A
Bearish Trend 13 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 13 days ago
80%
Bearish Trend 13 days ago
88%
Momentum
ODDS (%)
Bearish Trend 13 days ago
90%
Bearish Trend 13 days ago
82%
MACD
ODDS (%)
Bearish Trend 13 days ago
87%
Bearish Trend 13 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 13 days ago
85%
Bullish Trend 13 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 13 days ago
83%
Bullish Trend 13 days ago
81%
Advances
ODDS (%)
Bullish Trend 13 days ago
76%
Bullish Trend 14 days ago
76%
Declines
ODDS (%)
Bearish Trend 27 days ago
84%
Bearish Trend 19 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 13 days ago
71%
Bearish Trend 13 days ago
83%
Aroon
ODDS (%)
Bearish Trend 13 days ago
87%
Bullish Trend 13 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
STXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with LAB. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then LAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
+0.40%
LAB - CERS
52%
Loosely correlated
+5.83%
HBIO - CERS
49%
Loosely correlated
-23.84%
NNOX - CERS
46%
Loosely correlated
-0.58%
BFLY - CERS
45%
Loosely correlated
+3.95%
IRMD - CERS
45%
Loosely correlated
-1.69%
More

STXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, STXS has been loosely correlated with SMTI. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if STXS jumps, then SMTI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STXS
1D Price
Change %
STXS100%
-1.41%
SMTI - STXS
43%
Loosely correlated
-6.14%
BLFS - STXS
37%
Loosely correlated
+0.40%
TWST - STXS
36%
Loosely correlated
-3.67%
CERS - STXS
36%
Loosely correlated
+0.40%
RGEN - STXS
36%
Loosely correlated
-1.11%
More